Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

TWST 11.07.2024

Full Press ReleaseSEC FilingsOur TWST Tweets

About Gravity Analytica

Recent News

  • 02.03.2025 - Fiscal 2025 First Quarter Financial Results Conference Call
  • 01.22.2025 - Twist Bioscience to Report Fiscal 2025 First Quarter Financial Results on Monday, February 3, 2025
  • 01.14.2025 - 43rd Annual J.P. Morgan Healthcare Conference

Recent Filings

  • 01.14.2025 - 4 Statement of changes in beneficial ownership of securities
  • 01.10.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
  • 01.10.2025 - 144 Report of proposed sale of securities

Press Release Details

Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Nov 07, 2024
PDF Version

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Nov. 7, 2024--As required by the rules of theNasdaq Stock Market,Twist Bioscience Corporation(NASDAQ: TWST) (“Twist” or the “Company”), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it has granted a total of 147,800 equity awards, consisting of 110,300 restricted stock units (“RSUs”) to 43 recently hired individuals and an individually negotiated award of up to 37,500 performance stock units (“PSUs”) toColby Souders, a recently hired VP, in each case as an inducement material to their acceptance of employment with Twist. The employment inducement awards were granted under Twist’s Inducement Equity Incentive Plan and related form of restricted stock award agreement in accordance with Nasdaq Listing Rule 5635(c)(4).

The inducement plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Twist, or following a bona fide period of non-employment, as an inducement material to such individuals entering into employment with Twist, pursuant to Nasdaq Listing Rule 5635(c)(4).

The 110,300 RSUs vest over a 48-month period for each employee as follows: 25% vests on the one year anniversary of the start date of the employee (the “Vesting Commencement Date”), and 1/16 of the RSUs vest on each quarterly anniversary (or the last day of the month if no such day exists) of the Vesting Commencement Date thereafter, subject to the employee’s continued service through each vesting date. The up to 37,500 PSUs vest on achievement of certain performance metrics set by the Company’s Compensation Committee for the second half of fiscal year 2024 through fiscal year 2026 (which can be earned at 80%-150% of 100% target), subject, in each case, to his continued service through the applicable vesting dates.

AboutTwist Bioscience Corporation

Twist Bioscienceis a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by “writing” DNA on a silicon chip. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.

View source version onbusinesswire.com:https://www.businesswire.com/news/home/20241107954437/en/

For Investors:Angela BittingSVP, Corporate Affairs925-202-6211abitting@twistbioscience.com

For Media:Amanda HoulihanCommunications Manager774-265-5334ahoulihan@twistbioscience.com

Source:Twist Bioscience Corporation

  • Print Page
  • Email Page
  • Email Alerts
  • RSS Feeds
Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com